CannabiStada 17/1 – Stada

CannabiStada 17/1 - Stada

Product details

Origins

The Shiskaberry strain was created by mixing Afgan genetics and a Blueberry strain of cannabis.

Composition

CannabiStada 17/1 can be purchased in a variety of quantities. It targets a THC level of 15.8% and a CBD level of less than 1%. The containers of this product boast the whole dried plant flower. The buds of the plant are green, but they also have distinctive purple colourings. Unsurprisingly, this strain has a fruity aroma, particularly berry. The active ingredients of the cannabis plant include cannabinoids, terpenes, and flavonoids. The terpenes in this strain are Caryophyllene, Myrcene, and Limonene.

Storage

Storing your cannabis product correctly will prolong its life. Keep it in a cool, dry place and away from sunlight. It’s essential to keep this product (and any cannabinoid product) out of the reach of children and animals.

Dosing guidelines

The guidance provided here is not intended to be medical advice – patients will discuss their dosage guidelines with a medical professional independently before beginning their treatment.

If a medical cannabis product is purchased as a dried plant flower, then the patient can choose how they wish to consume it. For some, it suits them to add it to their food or drink. This enables the new treatment to fit in easily to any lifestyle. The effects of this method can last for ten hours, although it can take up to two hours to begin to feel the potential benefits. Patients can also choose to vape or smoke the product. This is a good idea for people who are already accustomed to this, however, it might not appeal to new users. It’s possible to feel the effects within five minutes of smoking or vaping medical cannabis.

Lab testing

Stada engages in all of the necessary safety and regulatory testing. Strict testing ensures that all of the products are safe for the patient to use. Independent testing also confirms all of the ingredients and establishes the THC potency.

Disclaimer

The current literature examining medical cannabis research is promising. However, no conclusive evidence has been drawn yet, therefore further scientific investigation is warranted. This could help to establish a standard dose for particular issues.

Related Posts